Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 5/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-Guggulsterone SCHEMBL7860363 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12153588 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL13304392 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL14193742 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL1650063 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL258031 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177528 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL177786 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| E-Guggulsterone SCHEMBL12858540 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR | |
| Guggulsterone SCHEMBL141657 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2HSD17B10ALDH1A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11540539-B2 | Reduced sodium food products | GENERAL MILLS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200281236-A1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3366677-B1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3466930-A1 | REDUCED SODIUM FOOD PRODUCT | GENERAL MILLS, INC. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20190090520-A1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2019-03-28 | — | — | US | disclosed |
| EP-2954037-B1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2956440-B1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2953934-B1 | REDUCED SODIUM FOOD PRODUCTS | GEN MILLS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170112823-A1 | COMPOSITIONS AND METHODS TO TREAT NEUROPATHY AND RELATED CONDITIONS | Health Naturally, LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112823-A1 | COMPOSITIONS AND METHODS TO TREAT NEUROPATHY AND RELATED CONDITIONS | Health Naturally, LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20150374021-A1 | REDUCED SODIUM FOOD PRODUCTS | GENERAL MILLS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2008058156-A9 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008058156-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7365218-B2 | Process for preparing guggulsterones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-04-29 | — | — | US | disclosed |
| US-7365218-B2 | Process for preparing guggulsterones | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112823-A1 | COMPOSITIONS AND METHODS TO TREAT NEUROPATHY AND RELATED CONDITIONS | TNF, PMP22, IL6 | SMN1; SMN2 31/4885HSD17B10 3471/4885ALDH1A1 845/4885 |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | SMN1; SMN2 3094/4885HSD17B10 550/4885ALDH1A1 4045/4885 |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | SGMS1, SGMS2, GGPS1 | SMN1; SMN2 3304/4885HSD17B10 769/4885ALDH1A1 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.